Literature DB >> 1828931

Structure-activity relationships of histamine H2-agonists, a new class of positive inotropic drugs.

A Buschauer1, G Baumann.   

Abstract

The cimetidine-like moiety in impromidine was replaced by either alternative partial structures known from H2-antagonists or by H2-nonspecific lipophilic groups. The most potent H2-agonists were found in a series of compounds structurally derived from the H1-antagonist pheniramine. Arpromidine (N1-[3-(4-fluorophenyl)-3-(2-pyridinyl)propyl]-N2-[3-(1H-imidazol-4- yl)propyl]guanidine) may be considered a new lead for the development of "cardiohistaminergics". This guanidine combines both about 100 times the potency of histamine in the isolated guinea-pig atrium (pD2 = 8.0) and H1-antagonistic activity (pA2 = 7.65) in the range of pheniramine. Analogues difluorinated in 3,4-(BU-E-75) or 3,5-position (BU-E-76) or chlorinated in 3,4-position (BU-E-64) are up to 160 times more potent H2-agonists than histamine. In contrast to other types of guanidines, in the arpromidine series the order of potency found in guinea-pig atria was in good agreement with the results from isolated perfused guinea-pig hearts. In particular, the two-fold halogenated arpromidine analogues proved to be more potent positive inotropic agents than impromidine with lower stimulating effects on heart rate and reduced arrhythmogenic properties.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828931     DOI: 10.1007/978-3-0348-7309-3_15

Source DB:  PubMed          Journal:  Agents Actions Suppl        ISSN: 0379-0363


  2 in total

1.  Different activities of impromidine and related phenyl-(pyridylalkyl)guanidines at cardiac and gastric H2 receptors.

Authors:  G Coruzzi; M Adami; C Pozzoli; A Buschauer; G Bertaccini
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

Review 2.  The Roles of Cardiovascular H2-Histamine Receptors Under Normal and Pathophysiological Conditions.

Authors:  Joachim Neumann; Uwe Kirchhefer; Stefan Dhein; Britt Hofmann; Ulrich Gergs
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.